Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 39 minutes ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $25 to $20.
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $25 to $20.